Market
What will be the outcome of CAR-T therapy trials for lupus by end of 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Published results in peer-reviewed medical journals or official trial results
Story
CAR-T Therapy Shows Promise for Lupus Amid Serious Side Effects
Nov 30, 2024, 01:46 PM
Chimeric Antigen Receptor T-cell (CAR-T) therapy, initially approved for certain blood cancers, is showing promise in early tests for treating autoimmune diseases such as lupus. This innovative therapy is designed to eliminate entire classes of immune cells, potentially addressing conditions like lupus. However, the treatment poses risks of serious side effects. Researchers are also exploring other gene and immune therapies, including a universal gene therapy for Diamond-Blackfan anemia, which aims to correct the disorder regardless of the patient’s specific mutation. Additionally, a drug approved for heart failure has demonstrated potential in killing aggressive ovarian cancer cells and resensitizing relapsed tumors to chemotherapy in preclinical studies. These advancements highlight significant progress in the use of gene and immune-based treatments for various diseases.
View original story
Similar markets
Unsuccessful due to safety issues • 25%
Inconclusive results • 25%
Successful with no safety issues • 25%
Successful with minor safety issues • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy, but safety concerns • 25%
Positive efficacy and safety results • 25%
Negative efficacy, but good safety • 25%
Harmful Effects • 25%
Moderate Improvement • 25%
Significant Improvement • 25%
No Improvement • 25%
Negative immunogenicity results • 25%
Negative safety results • 25%
Study inconclusive • 25%
Positive safety and immunogenicity results • 25%
Yes • 50%
No • 50%
Ongoing • 25%
Successful with FDA approval • 25%
Unsuccessful • 25%
Successful without FDA approval • 25%
Trial inconclusive • 25%
Successful with moderate efficacy • 25%
Successful with high efficacy • 25%
Unsuccessful • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Safe and effective • 25%
Neither safe nor effective • 25%
Effective but not safe • 25%
Safe but not effective • 25%
No improvement • 25%
Moderate improvement • 25%
Worsening condition • 25%
Significant improvement • 25%